Designed for Children

Sialanar® (400mcg/ml glycopyrronium bromide equivalent to 320mcg/ml glycopyrronium) is licensed for the symptomatic treatment of severe sialorrhoea in children and adolescents aged 3 years and older with chronic neurological disorders.1

New clinical data from the SALIVA Trial - the first and only double-blind, randomised, placebo-controlled study in sialorrhoea, that has investigated efficacy, tolerability and quality of life.2
Sialanar is Designed for Children

Tailored titration for flexible and accurate dosing1

60% less volume vs. 1mg/5ml glycopyrronium bromide oral solutions, helping to improve patient acceptability1,3-6

Minimal excipients to reduce toxicity risk - sugar, alcohol and sorbitol free1,7,8

Use the links below to explore

Sign up for Proveca Education Events

Proveca run educational sessions on a regular basis covering a variety of topics, register here to be the first to know what’s coming up or head to our resources section to catch up on previous sessions.

References

  1. Sialanar® SmPC (January 2023) https://www.medicines.org.uk/emc/product/2301 
  2. Fayoux P et al., Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: A randomized, double-blind, placebo-controlled trial. Developmental Medicine & Child Neurology 2024; 00: 1–9. DOI:10.1111/dmcn.15841. https://onlinelibrary.wiley.com/doi/10.1111/dmcn.15841 
  3. Glycopyrronium Bromide 1 mg/5 ml Oral Solution (Colonis Pharma) SmPC (September 2021) https://www.medicines.org.uk/emc/product/7344/smpc#gref 
  4. Glycopyrronium Bromide 1 mg/5 ml Oral Solution (Rosemont Pharmaceuticals Limited) SmPC (December 2021) https://www.medicines.org.uk/emc/product/13136/smpc 
  5. Glycopyrronium Bromide 1 mg/5 ml Oral Solution (Strandhaven Limited t/a Somex Pharma UK Limited) SmPC (July 2022) https://www.medicines.org.uk/emc/product/14104/smpc 
  6. Batchelor H & Marriot J. BJCP 2015. Formulations for Children: Problems and Solutions https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.12268 
  7. Rouaz K, et al. Excipients in the paediatric population: a review. Pharmaceutics 2021; 13(3): 387.
  8. Arthur S. How to identify and manage ‘problem’ excipients in medicines for children. The Pharmaceutical Journal 2017. Available at:https://pharmaceutical-journal.com/article/ld/how-to-identify-and-manage-problem-excipients-in-medicines-for-children 
  9. Reddihough, D et al. J of Paediatr and Child Health 2021, 37: 183-186

All reference links accessed April 2024

UK-SIA-24-0016 | April 2024

Please see below for information on how to report an adverse event in the UK or Republic of Ireland:

UK
Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Proveca Limited. Phone: 0333 200 1866 E-Mail: medinfo@proveca.com

Republic of Ireland
Adverse events should be reported. Reporting forms and information can be found at: www.hpra.ie.
Adverse events should also be reported to Proveca Limited. Phone: +44 333 200 1866 E-Mail: medinfo@proveca.com

You are now leaving a Proveca website.

Proveca are not responsible for the content on this website.

Continue